1. Decamps Mini D, Pelofi J, Treisser A. Off-label drug use of the misoprostol in gynecology & obstetrics: From a medico-economics benefit to a potential legal risk. Gynecol Obstet Fertil. 2015;43(6):453-8. [
DOI:10.1016/j.gyobfe.2015.04.010] [
PMID]
2. Stanton C, Nand DN, Koski A, Mirzabagi E, Brooke S, Grady B, et al. Accessibility and potency of uterotonic drugs purchased by simulated clients in four districts in India. BMC pregnancy and childbirth. 2014;14(1):386. [
DOI:10.1186/s12884-014-0386-y] [
PMID] [
PMCID]
3. Uncu Y, Karahasan M, Uyaniklar Ö, Uncu G. Prophylactic misoprostol for the prevention of postpartum hemorrhage: a randomized controlled trial. Eur Rev Med Pharmacol Sci. 2015;19(1):15-22.
4. Milani F, Sharami SH, Arjmandi S. Comparison of sublingual and vaginal misoprostol for second-trimester pregnancy terminations. J Family Reprod Health. 2014;8(1):41.
5. Sääv I, Kopp Kallner H, Fiala C, Gemzell-Danielsson K. Sublingual versus vaginal misoprostol for cervical dilatation 1 or 3 h prior to surgical abortion: a double-blinded RCT. Human Reproduction. 2015;30(6):1314-22. [
DOI:10.1093/humrep/dev071] [
PMID]
6. Milani F, Roya Faraji M, Kobra Bloukimoghadam M, Salma Momenzadeh M, et al. Comparison of 25 ĩg Sublingual and 50 ĩg Intravaginal Misoprostol for Cervical Ripening and Labor: A Randomized Controlled Equivalence Trial. Arch Iran Med. 2014;17(10):652.
7. Bulusu R, Ray P, Rani A, Handa P. Comparison of side effects of misoprostol by oral and rectal routes in active management of third stage of labour. J Evid Based Med Health. 2017;4(3):146-9. [
DOI:10.18410/jebmh/2017/29]
8. Smith JM, Baawo SD, Subah M, Sirtor-Gbassie V, Howe CJ, Ishola G, et al. Advance distribution of misoprostol for prevention of postpartum hemorrhage (PPH) at home births in two districts of Liberia. BMC Pregnancy Childbirth. 2014;14(1):189. [
DOI:10.1186/1471-2393-14-189] [
PMID] [
PMCID]
9. Duduyemi AO, Okafor IP, Oridota ES. Misoprostol, Magnesium Sulphate and Anti-shock garment: A knowledge, availability and utilization study at the Primary Health Care Level in Western Nigeria. PloS one. 2019;14(3):e0213491. [
DOI:10.1371/journal.pone.0213491] [
PMID] [
PMCID]
10. Shin HJ, Lee SR, Roh A-m, Lim Y-m, Jeong KA, Moon H-S, et al. Anaphylactic shock to vaginal misoprostol: a rare adverse reaction to a frequently used drug. Obstet Gynecol Sci. 2018;61(5):636-40. [
DOI:10.5468/ogs.2018.61.5.636] [
PMID] [
PMCID]
11. Aung HH, Soe A, Aye NN. Effect of misoprostol on the pharmacokinetics of sustained release diclofenac in Myanmar healthy male volunteers. Siriraj Medical Journal. 2017;69(2):75-9.
12. Wu HL, Marwah S, Wang P, Wang QM, Chen XW. Oral Misoprostol Versus Vaginal Misoprostol In Management Of Anembryonic Pregnancy: Faculty of Medicine, Cairo University; 2016. Sci Rep. 2017;7:1664.
13. Makled A, Alsaied A, Ismail O, Farhan S. Effect of Sublingual Misoprostol on Intraoperative Blood Loss During Abdominal Hysterectomy: Randomized Controlled Trial. Egypt J Hospital Med. 2017;69(1): 1692-7. [
DOI:10.12816/0040119]
14. Sweed MS, El-Saied MM, Abou-Gamrah AE, El-Sabaa HA, Abdel-Hamid MM, Hemeda H, et al. Rectal vs. sublingual misoprostol before cesarean section: double-blind, three-arm, randomized clinical trial. Arch gynecol obstet. 2018;298(6):1115-22. [
DOI:10.1007/s00404-018-4894-2] [
PMID]
15. Frye LJ, Byrne ME, Winikoff B. A crossover pharmacokinetic study of misoprostol by the oral, sublingual and buccal routes. The European Journal of Contraception & Reproductive Health Care. 2016;21(4):265-8. [
DOI:10.3109/13625187.2016.1168799] [
PMID]
18. Bajwa SK, Bajwa SJS, Kaur H, Goraya SPS, Singh A, Kaurishar H. Management of third stage of labor with misoprostol: A comparison of three routes of administration. Perspect Clin Res. 2012;3(3):102-8. [
DOI:10.4103/2229-3485.100666] [
PMID] [
PMCID]
19. Valadan M, Mojarad M, Feizabad E. The Effect of Various Dosages of Misoprostol for Cervical Preparation Before the Hysteroscopy. J Obstet Gynecol Cancer Res. 2020; 5 (3) :88-92. [
DOI:10.30699/jogcr.5.3.88]
20. Florek AG, Dellavalle RP. Case reports in medical education: a platform for training medical students, residents, and fellows in scientific writing and critical thinking. J Med Case Rep. 2016 Apr 6;10:86. [
DOI:10.1186/s13256-016-0851-5] [
PMID] [
PMCID]
21. Ortega-Loubon C, Culquichicón C, Correa R. The Importance of Writing and Publishing Case Reports During Medical Training. Cureus. 2017;9(12):e1964. [
DOI:10.7759/cureus.1964]
22. Cullen MW, Geske J, Anavekar N, McAdams J, Beliveau, ME; Ommen, SR and et al. Reinvigorating Continuing Medical Education:Meeting the Challenges of the Digital Age. Mayo Clin Proc. 2019;94(12):2501-9. [
DOI:10.1016/j.mayocp.2019.07.004] [
PMID]
24. Nayki U, Taner C, E, Mizrak T, Nayki C, Derin G: Uterine Rupture during Second Trimester Abortion with Misoprostol. Fetal Diagn Ther 2005;20:469-71. [
DOI:10.1159/000087115] [
PMID]
25. Kim JO1, Han JY, Choi JS, Ahn HK, Yang JH, Kang IS, Song MJ, Nava-Ocampo AA. Oral misoprostol and uterine rupture in the first trimester of pregnancy: a case report .Reprod Toxicol. 2005;20(4):575-7. [
DOI:10.1016/j.reprotox.2005.04.014] [
PMID]
26. Akhan SE, Iyibozkurt AC, Turfanda A. Unscarred uterine rupture after induction of labor with misoprostol: a case report. Clin Exp Obstet Gynecol. 2001;28(2):118-20.
27. Belmajdoub M, Alaoui FZF, Chaara H, Melhouf A. Uterine rupture in patients with healthy uterus: misoprostol complication (case study and literature review Pan Afr Med J. 2018;31:223. eCollection. [Article in French] [
DOI:10.11604/pamj.2018.31.223.12906]
28. Mazhar F, Sultana J, Shahzad A. Misoprostol-induced Acute Coronary Syndrome in a Premenopausal Woman: A Case Report with Literature Review. Current Drug Safety. 2018;13;65-8. [
DOI:10.2174/1574886312666171122100929] [
PMID]
30. Matthesen T1, Olsen RH, Bosselmann HS, Lidegaard. Cardiac arrest induced by vasospastic angina pectoris after vaginally administered misoprostol. Ugeskr Laeger. 2017; 179(26):V02170167. [Article in Danish]
32. Rouzi AA, Almarzouki A, Tallab F, Ashkar L. Medical management of early pregnancy failure with misoprostol with rupture of the cesarean section scar pregnancy.Clin Exp Obstet Gynecol. 2017;44(3):477-9. [
DOI:10.12891/ceog3422.2017] [
PMID]
33. Egbe TO, Halle-Ekane GE, Tchente CN, Nyemb JE, Belley-Priso E.Management of uterine rupture: a case report and review of the literature. BMC Res Notes. 2016 .21;9(1):492. [
DOI:10.1186/s13104-016-2295-9] [
PMID] [
PMCID]
36. Nunes ML, Friedrich MA, Loch LF. Association of misoprostol, Moebius syndrome and congenital central alveolar hypoventilation. Case report. Arq Neuropsiquiatr. 1999;57(1):88-91. [
DOI:10.1590/S0004-282X1999000100017] [
PMID]
37. Khabbaz AY, Usta IM, El-Hajj MI, Abu-Musa A, Seoud M, Nassar AH. Rupture of an unscarred uterus with misoprostol induction: case report and review of the literature. J Matern Fetal Med. 2001;10(2):141-5. [
DOI:10.1080/jmf.10.2.141.145-8] [
PMID]
38. Torriente MC. Silent Uterine Rupture with the Use of Misoprostol for Second Trimester Termination of Pregnancy: A Case Report. Obstet Gynecol Int. 2011;2011:584652. [
DOI:10.1155/2011/584652] [
PMID] [
PMCID]
39. Sánchez O1, Guerra D. Moebius syndrome due to the use of misoprostol. Case report. Invest Clin. 2003;44(2):147-53. [Article in Spanish]
41. Hofmeyr G, Milos D, Nikodem V, De Jager M. Limb reduction anomaly after failed misoprostol abortion. S Afr Med J. 1998;88(5):566.
45. Henderson CE, Hana RG, Woroch R, Reilly KD. Short interpregnancy interval and misoprostol as additive risks for uterine rupture: a case report. J Reprod Med. 2010;55(7-8):362-4.
48. Abbas AM, Sheha AM, Hussein RS, Talaat E, Ali MN. First-trimester rupture of a scarred uterus after use of sublingual misoprostol: a case report. Proceed Obstet Gynecol. 2016;6(2):1-6. [
DOI:10.17077/2154-4751.1317]
49. Stitely ML, Craw S, Africano E, Reid R. Uterine Scar Dehiscence Associated with Misoprostol Cervical Priming for Surgical Abortion: A Case Report. J Reprod Med. 2015;60(9-10):445-8.
50. Pallavee P, Samal R, Begum J, Ghose S. Foetal fibular hemimelia with focal femoral deficiency following prenatal misoprostol use: a case report. J Obstet Gynaecol. 2016;36(6):760-1. [
DOI:10.3109/01443615.2016.1157152] [
PMID]
51. Béné J, Alarcon P, Faucon M, Auffret M, Delfosse F, Becker T, et al. Anaphylactic shock after misoprostol in voluntary termination of pregnancy-a case report. Eur J Obstet Gynecol Reprod Biol. 2014;182:260-1. [
DOI:10.1016/j.ejogrb.2014.09.012] [
PMID]
52. Goffman D, Cole D, Bobby P, Garry D. Failed methotrexate termination of pregnancy: a case report. J Perinatol. 2006;26(10):645. [
DOI:10.1038/sj.jp.7211563] [
PMID]
53. Rosa RFM, Travi GM, Valiatti F, Zen PRG, Pinto LL, Kiss A, et al. Poland syndrome associated with an aberrant subclavian artery and vascular abnormalities of the retina in a child exposed to misoprostol during pregnancy. Birth Defects Res A Clin Mol Teratol. 2007;79(6):507-11. [
DOI:10.1002/bdra.20366] [
PMID]
54. Marchese JW, Mullen MG, Doherty Jr JH. Proximal femoral focal deficiency and fibular hemimelia associated with misoprostol use: a case report. Clin Dysmorphol. 2012;21(4):229-30. [
DOI:10.1097/MCD.0b013e3283590a95] [
PMID]
55. Muñoz-Franco F, Lacunza-Ruiz FJ, Vázquez-Andrés DJ, Rodríguez-Hernández JR, Coronary artery vasospasm after misoprostol treatment for incomplete abortion: a case report. Contraception, 2019;100 (6):498-501. [
DOI:10.1016/j.contraception.2019.08.003] [
PMID]
56. M.K. Ramadan MK, Darido S, Bazzi Z, et al.First-Trimester Placenta Percre-ta Causing Massive Vaginal Bleeding Following the Use of Misoprostol: A Case Report. Int J Clin Case. 2020;4:12-5.